H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Dova Pharmaceuticals and raised his price target on shares to $39 from $18 after the FDA approved the company's expansion of Doptelet clinical use in chronic immune thrombocytopenia, or cITP, in the U.S. The analyst noted that the convenient dosing for Doptelet, the lack of hepatotoxicity, and the potential pricing advantage "could be seen as helpful footing to adoption and increased patient compliance," and added that he sees, considering the safety profile of the drug, an increasing market potential for Doptelet in cITP subjects with decompensated liver function.